<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2021-03706_2-282-12263</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Evaluation of novel diagnostic methods for detection of progression from latent to active tuberculosis</narrative>
   <narrative xml:lang="SV">Utv&#xE4;rdering av nya diagnostiska tester f&#xF6;r detektion av progression fr&#xE5;n latent till aktiv tuberkulos</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Tuberculosis (TB) is the leading single infectious disease in terms of mortality worldwide. In low-income countries one-fifth of adult deaths are associated with TB. If left untreated, each person with active TB is estimated to infect 10 to 15 new individuals annually. Therefore, interrupting disease transmission by accurate early detection/diagnosis, paired with appropriate treatment is of major importance. One quarter of the world&#xB4;s population is estimated to be latently infected with Mycobacterium tuberculosis (Mtb) and as such are at lifelong risk of progressing to active TB. It is estimated that 10% of latently infected develop active TB. However, no tests currently exist that can accurately predict who will progress from latent to active TB.&#xA0;The purpose of this project is to evaluate two novel methods to detect progression from latent TB to active disease; 1) a multiplex FluoroSpot assay that is a further development of the clinically used single-plex T-Spot assay, and 2) immune response signatures based on cell and plasma profiling.&#xA0;This proposal takes advantage of a recently initiated EDCTP-funded prospective multicenter study (called ERASE-TB) that is designed to sample 2100 household contacts to individuals with active TB in Tanzania, Zimbabwe, and Mozambique. Samples will be collected at several timepoints over two years after confirmed exposure to Mtb, providing an optimal setting to evaluate the proposed diagnostic methods.</narrative>
   <narrative xml:lang="SV">Tuberkulos &#xE4;r den enskilt st&#xF6;rsta infektionssjukdomen som globalt leder till flest d&#xF6;dsfall varje &#xE5;r. Den drabbar fr&#xE4;mst l&#xE5;ginkomstl&#xE4;nder, d&#xE4;r upp till vart femte d&#xF6;dsfall hos vuxna &#xE4;r associerat med sjukdomen. Det &#xE4;r estimerat att ca 25% av jordens befolkning &#xE4;r infekterade med Mycobacterium tuberculosis (Mtb), den bacill som orsakar tuberkulos. Hos de allra flesta h&#xE5;lls infektionen i en vilande icke-smittsam form, men &#xF6;ver sin livstid kommer ca 10% av dessa utveckla en aktiv smittsam form. Varje smittsam individ ber&#xE4;knas sedan infektera 10&#x2013;15 nya individer. Den nuvarande behandlingen best&#xE5;r av kombinationspreparat som ges under 6 m&#xE5;nader, ofta med biverkningar, vilket f&#xF6;rsv&#xE5;rar f&#xF6;ljsamheten. D&#xE5; s&#xE5; m&#xE5;nga lever med en kontrollerad vilande infektion globalt s&#xE5; &#xE4;r det d&#xE4;rf&#xF6;r inte efterstr&#xE4;vansv&#xE4;rt att behandla alla. Dessutom skulle behandling p&#xE5; bred front snabbt leda till utveckling av resistenta stammar. Detta &#xE4;r redan ett problem p&#xE5; m&#xE5;nga platser och f&#xF6;rsv&#xE5;rar behandlingen markant. F&#xF6;r att stoppa spridningen av Mtb och utvecklingen av tuberkulos beh&#xF6;vs d&#xE4;rf&#xF6;r b&#xE4;ttre detektionsmetoder. Dessa b&#xF6;r kunna identifiera de som &#xE4;r infekterade och p&#xE5; v&#xE4;g att utveckla en aktiv smittsam sjukdom. F&#xF6;r n&#xE4;rvarande finns inga tester som klarar detta.&#xA0;I detta projekt utv&#xE4;rderas tv&#xE5; nya metoder f&#xF6;r deras kapacitet att identifiera individer som &#xE4;r p&#xE5; v&#xE4;g att utveckla aktiv smittsam sjukdom. Denna typ av studier &#xE4;r sv&#xE5;ra att genomf&#xF6;ra d&#xE5; man beh&#xF6;ver f&#xF6;lja ett stort antal individer med k&#xE4;nd Mtb exponering &#xF6;ver tid f&#xF6;r att se vilka som utvecklar en aktiv sjukdom. Man kan sedan anv&#xE4;nda tidigare insamlade prover fr&#xE5;n de individerna som utvecklade aktiv sjukdom och j&#xE4;mf&#xF6;ra med prover fr&#xE5;n andra individer som fortsatt att kontrollera sin infektion. Genom denna j&#xE4;mf&#xF6;relse kan man d&#xE5; hitta m&#xF6;nster, eller signaturer, som f&#xF6;ruts&#xE4;ger utvecklingen av aktiv sjukdom. Ett uppf&#xF6;ljande steg &#xE4;r sedan att &#xF6;vers&#xE4;tta dessa &#x201D;signaturer&#x201D; till diagnostiska tester.&#xA0;I detta projekt kommer vi att medverka i ett st&#xF6;rre europeiskt samarbetsprojekt d&#xE4;r man f&#xF6;ljer 2100 individer i Tanzania, Mo&#xE7;ambique, och Zimbabwe med k&#xE4;nd Mtb exponering &#xF6;ver tv&#xE5; &#xE5;r. Under de tv&#xE5; &#xE5;ren samlar vi in prover vid fyra tillf&#xE4;llen. Proverna anv&#xE4;nds sedan f&#xF6;r att unders&#xF6;ka individens immunsvar och att identifiera signaturer associerade med utveckling av aktiv sjukdom. Kan vi s&#xE4;kerst&#xE4;lla signaturer som f&#xF6;ruts&#xE4;ger utveckling av aktiv sjukdom med stor s&#xE4;kerhet s&#xE5; har vi en god start f&#xF6;r att utveckla b&#xE4;ttre diagnostiska tester. Dessa &#xE4;r sedan i sin tur kritiska f&#xF6;r att kontrollera den globala spridningen av tuberkulos.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2022-01-01" type="1"></activity-date>
  <activity-date iso-date="2024-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="TZ" percentage="100">
   <narrative xml:lang="EN">Tanzania, United Republic of</narrative>
  </recipient-country>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12263" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Tuberculosis control</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">43129.4232181791</value>
  </budget>
  <budget>
   <period-start iso-date="2023-01-01"></period-start>
   <period-end iso-date="2023-12-28"></period-end>
   <value currency="USD" value-date="2023-01-01">40214.6171693736</value>
  </budget>
  <budget>
   <period-start iso-date="2024-01-01"></period-start>
   <period-end iso-date="2024-12-28"></period-end>
   <value currency="USD" value-date="2024-01-01">46044.2001189241</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-11-25"></transaction-date>
   <value currency="USD" value-date="2021-11-25">517552.9620259068</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
